METHODS FOR TREATING A STRICTURE WITH A BOTULINUM TOXIN
Methods of treating a urethral stricture in a patient. The methods can include the step of administering an therapeutically effective amount of a botulinum toxin directly to a urethra of the patient, for example by use of a stent from which the botulinum toxin can elute or diffuse, thereby treating the urethra stricture.
1 . A method for treating a urologic stricture in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a botulinum toxin to a location of the urologic stricture, thereby treating the urologic stricture.
2 . The method of claim 1 , wherein the step of administering is accomplished utilizing a stent coated or impregnated with the botulinum toxin.
3 . The method of claim 1 wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F, G and combinations thereof.
4 . The method of claim 1 wherein the botulinum toxin is botulinum toxin type A.
5 . The method of claim 2 , wherein the stent is a self expanding stent.
6 . The method of claim 1 , wherein the neurotoxin is administered in a dose of about 0.001 units up to about 100 units.
7 . The method of claim 1 , wherein the stricture is a urethral stricture.
8 . A method for treating a stricture in a patient, the method comprising: administering a therapeutically effective amount of a botulinum toxin to a location of the stricture, wherein the location includes a urothelium and the patient is having or has had a stenting procedure, thereby treating the stricture in the patient.
9 . The method of claim 8 , wherein the step of administering is accomplished utilizing a stent coated or impregnated with the botulinum toxin.
10 . The method of claim 8 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F, G and combinations thereof.
11 . The method of claim 8 , wherein the botulinum toxin is botulinum toxin type A.
12 . The method of claim 9 , wherein the stent is a self expanding stent.
13 . The method of claim 8 , wherein the neurotoxin is administered in a dose of about 0.001 units up to about 100 units.
14 . The method of claim 8 , wherein the neurotoxin is administered in a salve, lotion, ointment, cream or emulsion.
15 . The method of claim 8 , wherein the stricture is a urethral stricture.
16 . A method for improving urine flow in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a botulinum toxin to a location of a urologic stricture, wherein the urologic stricture arises as a result of damage selected from the group consisting of tearing, scratching, stretching, scraping, bruising and inflammation.
17 . The method of claim 16 , wherein of administering is accomplished utilizing a stent coated or impregnated with the botulinum toxin.
18 . The method of claim 16 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F, G and combinations thereof.
19 . The method of claim 16 , wherein the neurotoxin is administered in a dose of about 0.001 units up to about 100 units.
20 . The method of claim 16 , wherein the stricture is not caused by a muscle contraction or by a muscle tissue spasm.